[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200000327A2 - Новые соединения аминотриазола, способ их получения и содержащие их фармацевтические композиции - Google Patents

Новые соединения аминотриазола, способ их получения и содержащие их фармацевтические композиции

Info

Publication number
EA200000327A2
EA200000327A2 EA200000327A EA200000327A EA200000327A2 EA 200000327 A2 EA200000327 A2 EA 200000327A2 EA 200000327 A EA200000327 A EA 200000327A EA 200000327 A EA200000327 A EA 200000327A EA 200000327 A2 EA200000327 A2 EA 200000327A2
Authority
EA
Eurasian Patent Office
Prior art keywords
group
aminotriazol
production
pharmaceutical compositions
new connections
Prior art date
Application number
EA200000327A
Other languages
English (en)
Other versions
EA003023B1 (ru
Inventor
Жан-Люк Фошер
Жан-Клод Ортюно
Жак Дюо
Жан Альбер Бутэн
Нижель Левенс
Original Assignee
Адир Э Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адир Э Компани filed Critical Адир Э Компани
Publication of EA200000327A2 publication Critical patent/EA200000327A2/ru
Publication of EA003023B1 publication Critical patent/EA003023B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Соединение формулы (I)где n представляет собой 0 или 1,W представляет собой -CO- группу или S(O)q группу, где q представляет собой 0, 1 или 2,G представляет G, G, Gили Gгруппу, как описано в описанииZ представляет собой алкильную группу или арил, гетероарил, арилалкил, арилалкенил, арилалкинил, гетероарилалкенил, гетероарилалкинил или гетероарилалкильную группу, каждая из которых может быть необязательно замещенной,A представляет фрагмент формулы, выбранный из -A-, -A-A-, -A-A- и -A-A-A-, где Aпредставляет собой группу алкилена и Aпредставляет фенилен, циклоалкилен, нафтилен или группу гетероарилена, каждая из которых может быть необязательно замещенной,R представляет собой атом водорода, алкильную группу или арил, гетероарил, арилалкил, арилалкенил, арилалкинил, гетероарилалкенил, гетероарилалкинил или группу гетероарилалкила, каждая из которых может быть необязательно замещенной,Rпредставляет собой алкильную группу или арил, гетероарил, арилалкил, арилалкенил, арилалкинил, гетероарилалкенил или гетероарилалкинил или группу гетероарилалкила, каждая из которых может быть необязательно замещенной. Лекарственные препараты.
EA200000327A 1999-04-15 2000-04-14 Новые соединения аминотриазола, способ их получения и содержащие их фармацевтические композиции EA003023B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904721A FR2792314B1 (fr) 1999-04-15 1999-04-15 Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
EA200000327A2 true EA200000327A2 (ru) 2000-10-30
EA003023B1 EA003023B1 (ru) 2002-12-26

Family

ID=9544433

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000327A EA003023B1 (ru) 1999-04-15 2000-04-14 Новые соединения аминотриазола, способ их получения и содержащие их фармацевтические композиции

Country Status (19)

Country Link
US (2) US6245916B1 (ru)
EP (1) EP1044970B1 (ru)
JP (1) JP2000309579A (ru)
KR (1) KR20010020732A (ru)
CN (1) CN1145616C (ru)
AT (1) ATE231133T1 (ru)
BR (1) BR0001602A (ru)
CA (1) CA2305940A1 (ru)
DE (1) DE60001190T2 (ru)
DK (1) DK1044970T3 (ru)
EA (1) EA003023B1 (ru)
ES (1) ES2190396T3 (ru)
FR (1) FR2792314B1 (ru)
HU (1) HUP0001562A3 (ru)
NO (1) NO20001964L (ru)
NZ (1) NZ504023A (ru)
PL (1) PL339690A1 (ru)
SI (1) SI1044970T1 (ru)
ZA (1) ZA200001908B (ru)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070499A1 (en) * 1999-11-08 2005-03-31 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
EP1381360A4 (en) * 2001-03-29 2009-12-02 Smithkline Beecham Corp COMPOUNDS AND METHODS FOR INHIBITING METAP2 IN MAMMALS
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) * 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
EP1799668A1 (en) * 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
EP1804792A1 (en) * 2004-09-20 2007-07-11 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
MX2007003332A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
US7592343B2 (en) * 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
BRPI0515488A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
JP4958787B2 (ja) * 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
BRPI0518241A (pt) 2004-11-01 2008-04-22 Amylin Pharmaceuticals Inc métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
WO2006129826A1 (ja) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDONE COMPOUND
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
CN101400261B (zh) * 2006-01-17 2013-07-10 斯蒂菲尔实验室公司 使用三唑化合物治疗炎症异常
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CA2697974C (en) 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
EA201070609A1 (ru) * 2007-11-14 2010-12-30 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINE DERIVATIVE
JP5383788B2 (ja) * 2008-03-19 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニコチン性アセチルコリン受容体モジュレーターとしての三置換された１，２，４−トリアゾール
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
TWI440634B (zh) 2008-05-09 2014-06-11 Janssen Pharmaceutica Nv 經三取代之吡唑類
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US8775245B2 (en) 2010-02-11 2014-07-08 News America Marketing Properties, Llc Secure coupon distribution
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
RS54112B1 (en) * 2010-10-01 2015-12-31 Taisho Pharmaceutical Co. Ltd DERIVAT 1,2,4-TRIAZOLONA
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2000515493A (ja) * 1996-03-29 2000-11-21 ジー．ディー．サール アンド カンパニー パラ―置換フェニレン誘導体
WO1998027063A1 (fr) * 1996-12-16 1998-06-25 Banyu Pharmaceutical Co., Ltd. Derives d'aminopyrazole
PE20000127A1 (es) * 1997-12-22 2000-03-14 Novartis Ag Derivado de bencenosulfonamida

Also Published As

Publication number Publication date
KR20010020732A (ko) 2001-03-15
CN1272493A (zh) 2000-11-08
HUP0001562A2 (hu) 2001-04-28
JP2000309579A (ja) 2000-11-07
US20010018522A1 (en) 2001-08-30
EP1044970B1 (fr) 2003-01-15
NZ504023A (en) 2000-10-27
ZA200001908B (en) 2000-10-31
ATE231133T1 (de) 2003-02-15
EP1044970A1 (fr) 2000-10-18
HUP0001562A3 (en) 2003-05-28
DE60001190T2 (de) 2003-10-09
SI1044970T1 (en) 2003-06-30
US6245916B1 (en) 2001-06-12
ES2190396T3 (es) 2003-08-01
US6596749B2 (en) 2003-07-22
CA2305940A1 (fr) 2000-10-15
CN1145616C (zh) 2004-04-14
PL339690A1 (en) 2000-10-23
NO20001964L (no) 2000-10-16
DE60001190D1 (de) 2003-02-20
NO20001964D0 (no) 2000-04-14
EA003023B1 (ru) 2002-12-26
DK1044970T3 (da) 2003-04-22
FR2792314A1 (fr) 2000-10-20
BR0001602A (pt) 2001-08-21
FR2792314B1 (fr) 2001-06-01
HU0001562D0 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
EA200000327A2 (ru) Новые соединения аминотриазола, способ их получения и содержащие их фармацевтические композиции
HRP20041042A2 (en) Novel substituted sulfamate anticonvulsant derivatives
HUP9802859A2 (hu) Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ATE25977T1 (de) Furanonderivate, verfahren zu ihrer herstellung und ihre verwendung.
EA200800235A1 (ru) Новые трициклические соединения, способ их получения и фармацевтические композиции, которые их содержат
ATE503746T1 (de) Neue imidazolidinderivate
EA200000431A2 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
ATE19776T1 (de) Neue substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
EA200000948A1 (ru) Новые полициклические азаиндолы, способ их получения и фармацевтические композиции, содержащие их
EA200300458A1 (ru) Новые соединения аминотриазолона, способ их получения и фармацевтические композиции, содержащие их
WO2008111637A1 (ja) 蛍光膜
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
EA200601106A1 (ru) Трициклические имидазопиридины для применения в качестве ингибиторов желудочной секреции
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
EA200200665A1 (ru) Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие
EA199900528A1 (ru) Новые производные эритромицина, способ их получения и применения в качетве медикаментов
EA199900156A1 (ru) Новые производные эритромицина, способ их получения и их применение в качестве медикаментов
AU539177B2 (en) Amino alkoxy pyrazoles
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
DE60043228D1 (de) Herstellungsverfahren von 2-cyanopyridinen
ATE318265T1 (de) Amidin-derivate, ihre herstellung und verwendung als medikamenten
EA200000261A3 (ru) Новые замещенные димерные соединения, способ их получения и содержащияся их фармацевтическая композиция

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU